MISSISSAUGA, ON, May 5, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual General Meeting of Shareholders held May 2, 2014 in Toronto, Ontario.
A total of 14,793,915 million common shares representing 59.16% of the Company's issued and outstanding common shares were voted in connection with the meeting. Shareholders voted in favour of all items of business put forth, including the appointment of PricewaterhouseCoopers Canada as the auditor of the Company and the election of all director nominees were as follows:
|Motions||% of Shares Voted For||% of Shares Voted Withhold|
|Elect Gerald P. McDole||99.92%||0.08%|
|Elect Dr. John D. Mull||99.88%||0.12%|
|Elect Stephen R. Wiseman||99.92%||0.08%|
|Elect Dr. Stefan Aigner||99.92%||0.08%|
|Elect Dr. William D. Claypool||99.92%||0.08%|
|Elect Thomas G. Wellner||99.92%||0.08%|
|Appointment of Auditors||99.99%||0.01%|
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.
SOURCE: Cipher Pharmaceuticals Inc.
For further information:
(416) 815-0700 ext 278
(416) 815-0080 fax
Chief Financial Officer
(905) 602-5840 ext 323
(905) 602-0628 fax